Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties

Matthew D. Hill(Arkansas State University), Andrew P. Degnan(Bristol-Myers Squibb (United States)), Ashvinikumar V. Gavai(Bristol-Myers Squibb (United States)), Claude Quesnelle(Bristol-Myers Squibb (United States)), Laura Monereau(Bristol-Myers Squibb (United States)), Christine Huang(Columbia University), Mikkel DeBenedetto(Bristol-Myers Squibb (United States)), Melissa Kramer(Bristol-Myers Squibb (United States)), Nirmala Raghavan(Bristol-Myers Squibb (United States)), Shilpa Madari(Bristol-Myers Squibb (United States)), Chunshan Xie(Bristol-Myers Squibb (United States)), John S. Tokarski(Bristol-Myers Squibb (Germany)), Derek Norris(Bristol-Myers Squibb (United States)), Tatyana Zvyaga(Bristol-Myers Squibb (Germany)), George V. Delucca(Bristol-Myers Squibb (United States)), Jean Simmermacher-Mayer(Bristol-Myers Squibb (United States)), Francis Lee(Bristol-Myers Squibb (United States)), Haiquan Fang(Bristol-Myers Squibb (United States)), Zuzana Haarhoff(Bristol-Myers Squibb (United States)), S. Sheriff(Bristol-Myers Squibb (United States)), Lisa Zhang(The University of Sydney), Richard A. Westhouse(Bristol-Myers Squibb (United States)), William D. Schmitz(Bristol-Myers Squibb (United States)), Caroline Fanslau(Bristol-Myers Squibb (United States)), Michael Sinz(Rutgers, The State University of New Jersey), Haiying Zhang(Abbott Fund), Chunhong Yan(Bristol-Myers Squibb (United States)), Hong Huang(Bristol-Myers Squibb (United States)), Eric Shields(Bristol-Myers Squibb (United States)), Ching Kim Tye(Bristol-Myers Squibb (United States)), J. S. Morrison(Bristol-Myers Squibb (United States)), Krista Menard(Bristol-Myers Squibb (United States))
ACS Medicinal Chemistry Letters
July 5, 2022
Cited by 10


Related Papers